Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin

We conducted a phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Fostriecin was administered intravenously over 60 min on days 1–5 at 4-week intervals. Dose was escalated from 2 mg m(−2)day(−1)to 20 mg m(−2)day(−1)in 20 patients. Drug pharmacokinetics was anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Jong, R S de, Mulder, N H, Uges, D R A, Sleijfer, D Th, Höppener, F J P, Groen, H J M, Willemse, P H B, Graaf, W T A van der, Vries, E G E de
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362650/
https://www.ncbi.nlm.nih.gov/pubmed/10070885
http://dx.doi.org/10.1038/sj.bjc.6690141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362650/
https://www.ncbi.nlm.nih.gov/pubmed/10070885
http://dx.doi.org/10.1038/sj.bjc.6690141

Ejemplares similares